Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study

Author:

Funder

Bill & Melinda Gates Foundation

UNSW Australia

Kirby Institute/UNSW

Bristol-Myers Squibb

GlaxoSmithKline

Johnson & Johnson

Merck Sharp & Dohme

Pfizer

Stendhal

Abbott

AbbVie

Boehringer Ingelheim

Gilead Sciences

Janssen Cilag

Roche

ViiV Healthcare

Bill and Melinda Gates Foundation

Gilead Sciences Inc

Australian Government Department of Health and Ageing

Mylan Inc

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference20 articles.

1. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach,2013

2. Haas D, Hicks C, Seekins D, et al. A phase 2, double-blind, placebo-controlled, dose-ranging study to assess the antiretroviral activity and safety of efavirenz (DMP 266) in combination with open-label zidovudine and lamivudine at 24 weeks (DMP 005). Fifth Conference on Retroviruses and Opportunistic Infections; Chicago, IL, USA; Feb 1–5, 1998. Abstract 698.

3. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial;Lancet,2014

4. A 12-item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity;Ware;Med Care,1996

5. The short-form version of the Depression Anxiety Stress Scales (DASS-21): construct validity and normative data in a large non-clinical sample;Henry;Br J Clin Psychol,2005

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3